drugset / Trial / NCT01012375

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

NCT01012375

Phase 2 Completed 135 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.

Timeline

Start
2009-11
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1446 Small molecule 10 mg Oral
Subject AZD1446 Small molecule 80 mg Oral